Treatment of Light Chain Deposition Disease: A Systematic Review.

IF 1.3 Q4 HEMATOLOGY
Journal of hematology Pub Date : 2022-08-01 Epub Date: 2022-08-30 DOI:10.14740/jh1038
Adeel Masood, Hamid Ehsan, Qamar Iqbal, Ahmed Salman, Hamza Hashmi
{"title":"Treatment of Light Chain Deposition Disease: A Systematic Review.","authors":"Adeel Masood,&nbsp;Hamid Ehsan,&nbsp;Qamar Iqbal,&nbsp;Ahmed Salman,&nbsp;Hamza Hashmi","doi":"10.14740/jh1038","DOIUrl":null,"url":null,"abstract":"<p><p>Light chain deposition disease (LCDD) is a rare hematologic disorder that can affect any organ but predominantly involves the kidneys. Existing literature is limited to case reports and small single-center retrospective series, explaining the lack of any treatment algorithms and management guidelines for patients with this disorder. In this systematic review of literature, we explored the role of standard and high-dose chemotherapy-autologous stem cell transplant for LCDD. A total of 11 studies were identified to evaluate the hematologic and renal responses to various treatment regimens. Autologous stem cell transplant and bortezomib-based regimens appear to have reasonable safety and efficacy for this rare hematologic disorder, albeit some statistical and analytical limitations. Large multicenter retrospective and prospective studies are needed to better elucidate the role of various chemotherapy regimens as well as autologous stem cell transplant for patients with LCDD.</p>","PeriodicalId":15964,"journal":{"name":"Journal of hematology","volume":"11 4","pages":"123-130"},"PeriodicalIF":1.3000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/34/02/jh-11-123.PMC9451548.pdf","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14740/jh1038","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/8/30 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 4

Abstract

Light chain deposition disease (LCDD) is a rare hematologic disorder that can affect any organ but predominantly involves the kidneys. Existing literature is limited to case reports and small single-center retrospective series, explaining the lack of any treatment algorithms and management guidelines for patients with this disorder. In this systematic review of literature, we explored the role of standard and high-dose chemotherapy-autologous stem cell transplant for LCDD. A total of 11 studies were identified to evaluate the hematologic and renal responses to various treatment regimens. Autologous stem cell transplant and bortezomib-based regimens appear to have reasonable safety and efficacy for this rare hematologic disorder, albeit some statistical and analytical limitations. Large multicenter retrospective and prospective studies are needed to better elucidate the role of various chemotherapy regimens as well as autologous stem cell transplant for patients with LCDD.

Abstract Image

Abstract Image

Abstract Image

轻链沉积病的治疗:系统综述。
轻链沉积病(LCDD)是一种罕见的血液疾病,可影响任何器官,但主要累及肾脏。现有文献仅限于病例报告和小型单中心回顾性系列,解释了缺乏任何治疗算法和管理指南的患者这种疾病。在这篇系统的文献综述中,我们探讨了标准和高剂量化疗-自体干细胞移植在LCDD中的作用。共有11项研究被确定,以评估对各种治疗方案的血液学和肾脏反应。自体干细胞移植和硼替佐米为基础的方案似乎对这种罕见的血液疾病具有合理的安全性和有效性,尽管存在一些统计和分析局限性。需要大规模的多中心回顾性和前瞻性研究来更好地阐明各种化疗方案以及自体干细胞移植对LCDD患者的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of hematology
Journal of hematology HEMATOLOGY-
自引率
0.00%
发文量
29
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信